Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™
October 21, 2020 08:00 ET
|
Trevi Therapeutics
Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF Phase 2b/3 PRISM Trial of Haduvio for Severe Pruritus in Patients with Prurigo Nodularis Reaches 50% Enrollment...
Trevi Therapeutics Announces the Hiring of Key Talent
October 13, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference
September 09, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Announces Second Quarter 2020 Financial Results and Business Update
August 13, 2020 16:05 ET
|
Trevi Therapeutics
Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial Strong Enrollment in PRISM Trial After Lifting of COVID-19 Restrictions Announces $14 Million Term Loan - Cash...
Trevi Therapeutics to Hold Virtual 2020 Annual Meeting of Stockholders
May 29, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., May 29, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces First Quarter 2020 Financial Results and Corporate Update
May 07, 2020 16:05 ET
|
Trevi Therapeutics
Sample Size Re-Estimation Analysis for PRISM Trial Expected in Mid-2020 New Patient Screening Re-Starting at PRISM Sites in the US and Europe Cash Position of $52.6 Million Expected to Fund...